These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 3497179)

  • 21. Immunochemical studies of plasma kallikrein.
    Bagdasarian A; Lahiri B; Talamo RC; Wong P; Colman RW
    J Clin Invest; 1974 Dec; 54(6):1444-54. PubMed ID: 4140197
    [TBL] [Abstract][Full Text] [Related]  

  • 22. C1 inhibitor: analysis of the role of amino acid residues within the reactive center loop in target protease recognition.
    Zahedi R; MacFarlane RC; Wisnieski JJ; Davis AE
    J Immunol; 2001 Aug; 167(3):1500-6. PubMed ID: 11466370
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasma kallikrein activation and inhibition during typhoid fever.
    Colman RW; Edelman R; Scott CF; Gilman RH
    J Clin Invest; 1978 Feb; 61(2):287-96. PubMed ID: 74379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prekallikrein activation in the adult respiratory distress syndrome.
    Schapira M; Gardaz JP; Py P; Lew PD; Perrin LH; Suter PM
    Bull Eur Physiopathol Respir; 1985; 21(3):237-41. PubMed ID: 3873975
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Contribution of the N-terminal and C-terminal domains of haemaphysalin to inhibition of activation of plasma kallikrein-kinin system.
    Kato N; Okayama T; Isawa H; Yuda M; Chinzei Y; Iwanaga S
    J Biochem; 2005 Sep; 138(3):225-35. PubMed ID: 16169873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hageman factor-dependent pathways: mechanism of initiation and bradykinin formation.
    Kaplan AP
    Fed Proc; 1983 Nov; 42(14):3123-7. PubMed ID: 6556144
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine358.
    Heeb MJ; Bischoff R; Courtney M; Griffin JH
    J Biol Chem; 1990 Feb; 265(4):2365-9. PubMed ID: 2298753
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mouse plasma trypsin inhibitors: inhibitory spectrum of contrapsin and alpha-1-antitrypsin.
    Takahara H; Sinohara H
    Thromb Res; 1982 Jul; 27(1):45-50. PubMed ID: 6214866
    [TBL] [Abstract][Full Text] [Related]  

  • 29. alpha(1)-Proteinase inhibitor mutants with specificity for plasma kallikrein and C1s but not C1.
    Sulikowski T; Bauer BA; Patston PA
    Protein Sci; 2002 Sep; 11(9):2230-6. PubMed ID: 12192078
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional analysis of the serpin domain of C1 inhibitor.
    Coutinho M; Aulak KS; Davis AE
    J Immunol; 1994 Oct; 153(8):3648-54. PubMed ID: 7930585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.
    Wachtfogel YT; Kucich U; Hack CE; Gluszko P; Niewiarowski S; Colman RW; Edmunds LH
    J Thorac Cardiovasc Surg; 1993 Jul; 106(1):1-9; discussion 9-10. PubMed ID: 7686593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation.
    Wachtfogel YT; Hack CE; Nuijens JH; Kettner C; Reilly TM; Knabb RM; Bischoff R; Tschesche H; Wenzel H; Kucich U
    Am J Physiol; 1995 Mar; 268(3 Pt 2):H1352-7. PubMed ID: 7535008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma prekallikrein assay: reversible inhibition of C-1 inhibitor by chloroform and its use in measuring prekallikrein in different mammalian species.
    Schmaier AH; Gustafson E; Idell S; Colman RW
    J Lab Clin Med; 1984 Dec; 104(6):882-92. PubMed ID: 6209352
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of the P2 residue of complement 1 inhibitor (Ala443) in determination of target protease specificity: inhibition of complement and contact system proteases.
    Zahedi R; Wisnieski J; Davis AE
    J Immunol; 1997 Jul; 159(2):983-8. PubMed ID: 9218620
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The appended tail region of heparin cofactor II and additional reactive centre loop mutations combine to increase the reactivity and specificity of alpha1-proteinase inhibitor M358R for thrombin.
    Sutherland JS; Bhakta V; Sheffield WP
    Thromb Haemost; 2007 Nov; 98(5):1014-23. PubMed ID: 18000606
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of the P2 residue in determining the specificity of serpins.
    Djie MZ; Le Bonniec BF; Hopkins PC; Hipler K; Stone SR
    Biochemistry; 1996 Sep; 35(35):11461-9. PubMed ID: 8784202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling of serpin-protease complexes: antithrombin-thrombin, alpha 1-antitrypsin (358Met-->Arg)-thrombin, alpha 1-antitrypsin (358Met-->Arg)-trypsin, and antitrypsin-elastase.
    Whisstock J; Lesk AM; Carrell R
    Proteins; 1996 Nov; 26(3):288-303. PubMed ID: 8953650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The challenge of hereditary angioneurotic edema.
    Donaldson VH
    N Engl J Med; 1983 May; 308(18):1094-5. PubMed ID: 6601241
    [No Abstract]   [Full Text] [Related]  

  • 39. Proteases and protease inhibitors in cerulein-induced acute pancreatitis in rats.
    Kruse P; Lasson A; Hage E
    J Surg Res; 1999 Aug; 85(2):294-300. PubMed ID: 10423332
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock.
    Jansen PM; Eisele B; de Jong IW; Chang A; Delvos U; Taylor FB; Hack CE
    J Immunol; 1998 Jan; 160(1):475-84. PubMed ID: 9552006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.